×
About 32,868 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,967 results

UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in ...
https://doi.org/10.1016/j.neuron.2021.04.023
Neuron Zhang K, Wang A et. al.

May 15th, 2021 - Expansion of a hexanucleotide repeat GGGGCC (G4C2) in the intron of the C9ORF72 gene is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD). Transcripts carrying G4C2 repeat expansions genera...

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.
https://doi.org/10.1007/s13311-021-01064-z 10.1016/j.mayocp.2018.04.007 10.1002/acn3.51098 10.1007/s00401-019-01964-7 10.1016/S1474-4422(18)30394-6 10.1097/WCO.0000000000000854 10.1002/med.21661 10.1038/nrd.2018.168 10.1016/j.coisb.2017.04.015 10.1038/nrg2918 10.1056/NEJMe078114 10.1002/wsbm.1489 10.1038/s41540-020-00168-0 10.1073/pnas.0701361104 10.1038/s41467-018-05116-5 10.1371/journal.pcbi.1008686 10.1186/s12859-021-04076-w 10.1093/nar/gku1204 10.1093/nar/gkh070 10.1093/nar/gkr930 10.1093/nar/gkt1115 10.1093/nar/gks1147 10.1093/bioinformatics/btp618 10.1152/physiolgenomics.00087.2001 10.1007/s00401-012-1027-z 10.1126/science.1132939 10.1073/pnas.0506580102 10.1080/00949659908811936 10.1080/00949659708811844 10.1016/S0167-9473(02)00279-7 10.1023/A:1008943611855 10.1017/S0003480096005957 10.1002/(SICI)1099-095X(199801/02)9:1<37::AID-ENV284>3.0.CO;2-T 10.1080/00949658908811106 10.1093/nar/gkv1070 10.1093/nar/gkw377 10.1016/S0304-3940(03)00006-5 10.1016/j.neulet.2010.08.005 10.1038/sj.npp.1301534 10.1016/j.ejphar.2007.09.009 10.1016/j.neuropharm.2017.06.016 10.1124/jpet.105.087965 10.1038/sj.bjp.0707253 10.1016/0028-3908(83)90238-1 10.1016/j.bbi.2020.04.038 10.1080/21556660.2020.1745209 10.12740/PP/OnlineFirst/90687 10.1007/s00213-013-3232-4 10.1038/sc.2008.154 10.1136/jnnp-2017-315607 10.1016/B978-0-12-394623-2.00014-7 10.1126/science.8209258 10.1016/j.arr.2020.101121 10.1016/j.pharmthera.2019.06.006 10.1080/21678421.2019.1632346 10.3988/jcn.2014.10.4.342 10.1080/21678421.2019.1573850 10.1186/s12974-016-0658-8 10.1007/s12035-014-9019-8
Neurotherapeutics : the Journal of the American Society F... Fiscon G, Conte F et. al.

May 14th, 2021 - The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and ...

Validation of The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in behavioural ...
https://doi.org/10.1002/gps.5566
International Journal of Geriatric Psychiatry; De Icaza Valenzuela MM, Bak TH et. al.

May 13th, 2021 - The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was developed to assess cognitive and behavioural changes in an anterior frontotemporal syndrome (executive functions, language, fluency and behaviour), common in Amyotrophic Lateral Sclero...

Articulatory Correlates of Stress Pattern Disturbances in Talkers With Dysarthria.
https://doi.org/10.1044/2021_JSLHR-20-00299
Journal of Speech, Language, and Hearing Research : JSLHR; Kim D, Kuruvilla-Dugdale M et. al.

May 13th, 2021 - Purpose Reduced stress commonly occurs in talkers with Parkinson's disease (PD), whereas excessive and equal stress is frequently associated with dysarthria of talkers with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). This stud...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  33 results see all →

Clinicaltrials.gov  16,381 results

UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in ...
https://doi.org/10.1016/j.neuron.2021.04.023
Neuron Zhang K, Wang A et. al.

May 15th, 2021 - Expansion of a hexanucleotide repeat GGGGCC (G4C2) in the intron of the C9ORF72 gene is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD). Transcripts carrying G4C2 repeat expansions genera...

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.
https://doi.org/10.1007/s13311-021-01064-z 10.1016/j.mayocp.2018.04.007 10.1002/acn3.51098 10.1007/s00401-019-01964-7 10.1016/S1474-4422(18)30394-6 10.1097/WCO.0000000000000854 10.1002/med.21661 10.1038/nrd.2018.168 10.1016/j.coisb.2017.04.015 10.1038/nrg2918 10.1056/NEJMe078114 10.1002/wsbm.1489 10.1038/s41540-020-00168-0 10.1073/pnas.0701361104 10.1038/s41467-018-05116-5 10.1371/journal.pcbi.1008686 10.1186/s12859-021-04076-w 10.1093/nar/gku1204 10.1093/nar/gkh070 10.1093/nar/gkr930 10.1093/nar/gkt1115 10.1093/nar/gks1147 10.1093/bioinformatics/btp618 10.1152/physiolgenomics.00087.2001 10.1007/s00401-012-1027-z 10.1126/science.1132939 10.1073/pnas.0506580102 10.1080/00949659908811936 10.1080/00949659708811844 10.1016/S0167-9473(02)00279-7 10.1023/A:1008943611855 10.1017/S0003480096005957 10.1002/(SICI)1099-095X(199801/02)9:1<37::AID-ENV284>3.0.CO;2-T 10.1080/00949658908811106 10.1093/nar/gkv1070 10.1093/nar/gkw377 10.1016/S0304-3940(03)00006-5 10.1016/j.neulet.2010.08.005 10.1038/sj.npp.1301534 10.1016/j.ejphar.2007.09.009 10.1016/j.neuropharm.2017.06.016 10.1124/jpet.105.087965 10.1038/sj.bjp.0707253 10.1016/0028-3908(83)90238-1 10.1016/j.bbi.2020.04.038 10.1080/21556660.2020.1745209 10.12740/PP/OnlineFirst/90687 10.1007/s00213-013-3232-4 10.1038/sc.2008.154 10.1136/jnnp-2017-315607 10.1016/B978-0-12-394623-2.00014-7 10.1126/science.8209258 10.1016/j.arr.2020.101121 10.1016/j.pharmthera.2019.06.006 10.1080/21678421.2019.1632346 10.3988/jcn.2014.10.4.342 10.1080/21678421.2019.1573850 10.1186/s12974-016-0658-8 10.1007/s12035-014-9019-8
Neurotherapeutics : the Journal of the American Society F... Fiscon G, Conte F et. al.

May 14th, 2021 - The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and ...

Validation of The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in behavioural ...
https://doi.org/10.1002/gps.5566
International Journal of Geriatric Psychiatry; De Icaza Valenzuela MM, Bak TH et. al.

May 13th, 2021 - The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was developed to assess cognitive and behavioural changes in an anterior frontotemporal syndrome (executive functions, language, fluency and behaviour), common in Amyotrophic Lateral Sclero...

Articulatory Correlates of Stress Pattern Disturbances in Talkers With Dysarthria.
https://doi.org/10.1044/2021_JSLHR-20-00299
Journal of Speech, Language, and Hearing Research : JSLHR; Kim D, Kuruvilla-Dugdale M et. al.

May 13th, 2021 - Purpose Reduced stress commonly occurs in talkers with Parkinson's disease (PD), whereas excessive and equal stress is frequently associated with dysarthria of talkers with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). This stud...

see more →

News  459 results

Twofold Increased ALS Risk in Manual Laborers
https://www.medscape.com/viewarticle/949580

Apr 19th, 2021 - Blue-collar workers, particularly carpenters and construction workers, have a significantly increased risk for amyotrophic lateral sclerosis (ALS) compared with white-collar workers, new research shows. Investigators found manual laborers had a tw...

Theatrics, Hypnosis, and the Roots of Modern Neurology
https://www.medscape.com/viewarticle/947504

Mar 14th, 2021 - "Symptoms, then, are in reality nothing but a cry from suffering organs" – Jean-Martin Charcot Nearly 130 years after his death, Jean-Martin Charcot's name still resonates with modern neurologists. The famed 19th century French physician made myri...

New Compound Promising for ALS, Other Upper Motor Neuron Diseases
https://www.medscape.com/viewarticle/947056

Mar 10th, 2021 - NEW YORK (Reuters Health) - A new compound, NU-9, improved diseased upper motor neurons (UMN) in mice and shows promise for treating amyotrophic lateral sclerosis (ALS) in humans, though more work is needed before a clinical trial can be started, ...

After a Decade of Lobbying, ALS Patients Gain Faster Access to Disability Payments
https://www.medscape.com/viewarticle/944474

Jan 20th, 2021 - Anita Baron first noticed something was wrong in August 2018, when she began to drool. Her dentist chalked it up to a problem with her jaw. Then her speech became slurred. She managed to keep her company, which offers financing to small businesses...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.staging.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

see more →

Patient Education  19 results see all →